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A-26-year old female patient with chronic Budd-Chiari syndrome due to diﬀerent underlying blood disorders applied for a two-
year followup of the liver with Gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic-acid-(Gd-EOB-DTPA-) enhanced MRI.
The liver function tests were raised. Besides showing a progressive hepatosplenomegaly and a cirrhotic liver alteration, the MRI
revealed multiple new nodular lesions in all liver segments. These lesions showed typical patterns in the precontrast images, while
there was an arterial and a persistent portal venous enhancement. In the hepatobiliary liver-speciﬁc late phase, a central “washout”
and a persistent rim enhancement were observed (target sign). The additionally performed contrast-enhanced ultrasonography
showed a strong zentrifugal arterial enhancement of the lesions followed by an isoechoic enhancement in the portal venous
and delayed liver phase. Histologically these lesions turned out as focal nodular hyperplasias (FNH) or FNH-like lesions, also
known as large regenerative nodules (LRNs). Diﬀerentiation between regenerative nodules like LRN and hepatocellular carcinoma
(HCC) in cirrhotic livers is crucial, and the target sign in the hepatobiliary phase of Gd-EOB-DTPA as well as the centrifugal
arterial enhancement followed by an isoenhancement during a CEUS might be useful for establishing the correct diagnosis of such
hypervascular lesions with proliferated and likely aberrant bile ducts.
1.Introduction
The Budd-Chiari syndrome (BCS) is a rare vascular liver
disease with a potentially severe course caused by drain
disorder of the liver veins or of the inferior vena cava (IVC)
resulting in portal hypertension. The etiology, the level of
hepatic outﬂow tract obstruction, and the course of the
disease diﬀer between western and Asian countries [1]. Liver
vein obstruction due to thrombosis predominates in western
countries, whereas in China, Japan, and India, BCS is mainly
caused by membranous obstruction of the IVC [2].
Therapeutic options include the positioning of shunts or
IVC bypasses, the radical membrane resection with throm-
bus extraction, thrombolysis, angioplasty, stenting, and anti-
coagulation [3].
Progressed BCS may be associated with the development
of liver cirrhosis and diﬀerent focal liver nodes. In this
context, the development of regenerative nodules which are
resembling focal nodular hyperplasia (FNH) is likely [4]b u t
has to be deﬁnitely diﬀerentiated from HCC nodules.
2. Case Presentation
A-26-year-old female patient with chronic BCS known for
three years applied for a two-year followup of the liver with
magnetic resonance imaging (MRI). Further known diag-
noses were a polycythaemia vera, a hereditary thrombophilia
associated with a heterozygous factor V Leiden, a heterozy-
gous factor VII deﬁciency, and a thalassemia. At the day of
examination, the patient complained about abdominal dis-
comfort lasting for weeks. Laboratory tests showed increased
levels of bilirubin (27µmol/L, norm: 5–18µmol/L) and
gamma glutamyl transpeptidase (GGT, 143U/L, norm: 8–
49U/L) with otherwise normal transaminases, an increased2 Case Reports in Radiology
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Figure 1: In T2-weighted HASTE sequence, (a) the reference lesion reveals hypointense (arrow). In precontrast T1-weighted FLASH
2D sequence, it is inhomogeneous hyperintense (arrow) (b). Arterial phase (c) and portal venous phase (d) T1-weighted VIBE show a
progredient enhancement (arrows).
alkalinephosphatase(ALP,145U/L,norm:31–108U/L),and
an increased international normalized ratio (INR, 1.5, norm:
INR < 1.3).
The MRI was conducted on a 1.5 Tesla Avanto (Siemens,
Erlangen, Germany) with a single body-array coil at the
upper abdomen. Gd-EOB-DTPA (Primovist, Bayer Schering
Pharma, Berlin, Germany) was applied as contrast medium
viacubitaladituswithadosageof0.1mL/kgbodyweightand
a ﬂow rate of 2mL/s. Gd-EOB-DTPA is a new gadolinium-
based MRI contrast agent with a liver-speciﬁc hepatobiliary
uptake and a liver-speciﬁc enhancement which starts about
10min p.i. Subsequent to the precontrast sequences (T2-
weighted HASTE, axial and coronal plane; T2-weighted TSE,
T1-weighted FLASH 2D and VIBE with fat saturation (FS),
axial plane), a dynamic T1-weighted examination (VIBE FS,
axial plane; arterial: 30s p.i., portal venous: 60s p.i.) was
carried out. The late hepatobiliary phase after 20min p.i.
(T1-weighted Flash 2D FS, axial and coronal plane, 20min
p.i.) completed the examination.
The CEUS was done on an Acuson Sequoia (Siemens,
Mountain View, CA, USA) using a 4.2MHz convex scanner
in a contrast-pulse-sequency- (CPS-) mode (mechanical in-
dex, MI = 0.21). A sulphur-hexaﬂuoride-based contrast
agent (BR1, SonoVue, Bracco, Milano, Italy) was applied
again over a cubital access, this time manually with a
subsequent NaCl-Bolus of 10mL. After the conventional
B-mode imaging including a Doppler examination, the
dynamic ultrasound was carried out over a time period of
5min. The arterial phase, the portal venous phase, and the
liver late phase (>2min p.i.) were documented.
In the two-year interval, a progressive hepatosplenomeg-
aly (craniocaudal extention of 20cm versus 16cm in the
preliminaryinvestigation)appearedaswellasacirrhoticliver
alteration. Liver parenchyma showed an inhomogeneous
perfusionpatterninthedynamicMRIsequencesandpooling
of contrast medium in the more central areas surrounding
the porta hepatis during the late phase. Newly developed
intrahepatic collaterals were also found and best visualized
in the portal venous phase. Additionally multiple, also newly
developed,nodularlesionsappearedinallliversegments,the
largest with a diameter of about 2cm in segment VIII.
These lesions were hypointense on T2-weighted images
andinhomogeneoushyperintenseonprecontrastT1-weight-
ed sequences. On dynamic postcontrast examination, all
lesions showed arterial enhancement which persisted in por-
tal venous phase (Figure 1). In the hepatobiliary liver-
speciﬁc late phase, a central “washout” and a persistent rim
enhancement (target sign), at least in larger lesions, was
observed (Figure 2).
CEUS showed, more distinctively than MRI, a strong
arterial enhancement, which started in the center of the
lesions and propagated to the peripheral parts. During the
portal venous and the delayed liver phase, the lesions then
appeared isoechoic compared with the surrounding liver
parenchyma (Figure 3).
An ultrasound-guided biopsy of one of the lesions in
segment VIII revealed an FNH or in the clinical context and
together with the image ﬁndings likely an FNH-like lesion,
also known as a large regenerative nodule (LRN) [5], and
a cirrhotic alteration of the surrounding liver parenchyma
(Figure 4).Case Reports in Radiology 3
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Figure 2: As the multiple lesions show a homogeneous enhancement in portal venous phase (a) (T1-weighted VIBE sequence), there is a
central “washout” with a peripheral pooling of contrast agent (white arrow) in late phase (b) (T1-weighted FLASH sequence, 20min p.i.).
This is likely to be due to a missing washin of the more central parts. Additionally, there is an evidence of an inhomogeneous hilar pooling of
the contrast agent, predominantly in the left liver lobe (green arrow). Contrast agent level in the ductus hepatocholedochus (yellow arrow).
(a) (b) (c)
Figure 3: CEUS shows a more explicit centrifugal arterial (a) 16s p.i.; (b) (17s p.i.) and a liver like portal venous enhancement (c) (50s p.i.)
of the reference lesion (arrow).
(a) (b)
Figure 4:Histologicalpreparation:(a)thickenedarterialvascularwall(arrows),proliferationofbileductsandofinﬂammatorycells(black),
and normal hepatocytes/liver parenchyma (white) (b) dropout of hepatocytes as a sign of cirrhosis of the liver, liver vein (red), and normal
liver parenchyma (light blue).4 Case Reports in Radiology
3. Discussion
The development of regenerative nodules with FNH aspect
in chronic BCS is a known condition. It is assumed that the
impaired portal perfusion in chronic BCS is compensated by
a progressive enlargement of the hepatic artery to maintain
a steady hepatic inﬂow. This vascular imbalance with an
increase of arterial perfusion in liver parenchyma is expected
tosupportthedevelopmentoflargeregenerativenodules,the
arterial arborisation, and the development of aberrant bile
ducts in these nodules being responsible for a histological
FNH aspect [4, 5]. However, there are mainly two diﬀerent
types of nodular lesions that have been described with the
history of impaired liver circulation: nodular regenerative
hyperplasia (NRH) and large regenerative nodules (LRNs),
the latter are the more FNH-like lesions [5, 6]. In general,
these nodules develop independently from liver cirrhosis,
and LRNs seem to be associated with BCS [5].
MRI appearance of the BCS depends on duration and
extent of the obstruction as well as on portal venous ﬂux
changes.Theacutestageshowscongestionandhepatomegaly
followed by a mild atrophy of liver cells; intrahepatic and
subcapsular collaterals emerge. Chronic BCS turns into liver
cirrhosis with focal or generalized nodular regrouping of
liver parenchyma [7].
FNH-like lesions within a chronic BCS have been de-
scribed in literature as small hypervascular lesions. Lesions
bigger than 1cm often show a central scar [8].
In this case, dynamic MRI and CEUS showed typical
featuresofanFNHoranFNH-likelesionintermsofastrong
arterialenhancement,followedbyacontrastagentpoolingin
portal venous phase (Figures 1 and 3). MRI with GD-EOB-
DTPA then showed a central “washout” of the lesions in the
hepatobiliaryliver-speciﬁclatephasewhilethecontrastagent
retained in the more peripheral part of the lesions (target-
sign, Figure 2). Although we use the term “wash-out”, this
is likely to be a missing washin or a missing pooling of the
lesion parts which did not have proliferated aberrant bile
ducts. This observed target sign in the hepatobiliary phase
of Gd-EOB-DTPA might be useful for the characterisation
of such lesions.
If we consider these FNH-like lesions as LRN, the pre-
contrast T1- and T2-weighted sequences were rather typical
(Figure 1). LRNs are usually hyperintense compared to the
surrounding liver parenchyma in T1-weighted images and
iso- to slightly hypointens in T2-weighted images [9–11].
This is diﬀerent compared to regular FNHs which are usually
slightly hypointense in T1 and slightly hyperintense in T2
[12].
Here, the lesions were hyperintense with merely cen-
tral hypointensity on precontrast T1-weighted sequences
(FLASH 2D, VIBE) and hypointense on the T2-weighted
sequences so as to assume LRN [13]. The lesions are hyper-
intense on T1 because of a higher load of copper, while the
hypointense appearance in T2-weighted images is likely due
to the more regenerative character of the lesions compared
with usual FNH.
Contrast-enhanced MRI (Figures 1 and 2) and CEUS
(Figure 3) may therefore show the typical features of an LRN
together with typical FNH pattern. In this case, an arterial
enhancement was typical together with a venous pooling
while a feeding artery, a spokewheel pattern, or a central
scar could not be recognised. In addition, we found the de-
scribed target sign on MRI and a clear visible centrifugal
enhancement on CEUS.
LRN with FNH aspects in BCS are generally stable. Bi-
opsy seems to be necessary only for overall uncharacteristic
ﬁndings. Nevertheless, liver cell adenoma and highly diﬀer-
entiated hepatocellular carcinoma should be considered as
diﬀerential diagnoses. Therefore, continuous controls com-
bined with regular serum alpha-fetoprotein analysis are
required.
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